vs
Protalix BioTherapeutics, Inc.（PLX）与Ready Capital Corp（RC）财务数据对比。点击上方公司名可切换其他公司
Ready Capital Corp的季度营收约是Protalix BioTherapeutics, Inc.的1.4倍（$13.1M vs $9.1M），Protalix BioTherapeutics, Inc.净利率更高（-60.3% vs -1772.7%，领先1712.3%），Protalix BioTherapeutics, Inc.同比增速更快（-49.9% vs -73.8%），过去两年Protalix BioTherapeutics, Inc.的营收复合增速更高（-6.7% vs -48.0%）
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
Ready Capital Corp是一家总部位于美国的商业地产金融企业，提供多户住宅贷款、小型商业地产抵押贷款、建筑融资及抵押贷款服务等定制化解决方案，核心客户覆盖美国各地的房地产投资者、小型企业运营者及地产开发商。
PLX vs RC — 直观对比
营收规模更大
RC
是对方的1.4倍
$9.1M
营收增速更快
PLX
高出23.9%
-73.8%
净利率更高
PLX
高出1712.3%
-1772.7%
两年增速更快
PLX
近两年复合增速
-48.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.1M | $13.1M |
| 净利润 | $-5.5M | $-232.6M |
| 毛利率 | 49.4% | — |
| 营业利润率 | -51.1% | -2013.3% |
| 净利率 | -60.3% | -1772.7% |
| 营收同比 | -49.9% | -73.8% |
| 净利润同比 | -184.8% | 26.1% |
| 每股收益（稀释后） | $-0.06 | $-1.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLXRC
| Q4 25 | $9.1M | $13.1M | ||
| Q3 25 | $17.9M | $85.4M | ||
| Q2 25 | $15.7M | $16.9M | ||
| Q1 25 | $10.1M | $40.2M | ||
| Q4 24 | $18.2M | $50.1M | ||
| Q3 24 | $18.0M | $107.2M | ||
| Q2 24 | $13.5M | $51.0M | ||
| Q1 24 | — | $48.5M |
净利润PLXRC
| Q4 25 | $-5.5M | $-232.6M | ||
| Q3 25 | $2.4M | $-16.7M | ||
| Q2 25 | $164.0K | $-53.7M | ||
| Q1 25 | $-3.6M | $82.0M | ||
| Q4 24 | $6.5M | $-314.8M | ||
| Q3 24 | $3.2M | $-7.3M | ||
| Q2 24 | $-2.2M | $-34.2M | ||
| Q1 24 | — | $-74.2M |
毛利率PLXRC
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 62.5% | — | ||
| Q1 25 | 19.1% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — | ||
| Q1 24 | — | — |
营业利润率PLXRC
| Q4 25 | -51.1% | -2013.3% | ||
| Q3 25 | 11.9% | -31.5% | ||
| Q2 25 | 7.5% | -524.9% | ||
| Q1 25 | -41.0% | — | ||
| Q4 24 | 39.6% | -629.0% | ||
| Q3 24 | 22.2% | -14.8% | ||
| Q2 24 | -18.0% | -157.0% | ||
| Q1 24 | — | -217.9% |
净利率PLXRC
| Q4 25 | -60.3% | -1772.7% | ||
| Q3 25 | 13.2% | -19.6% | ||
| Q2 25 | 1.0% | -317.7% | ||
| Q1 25 | -35.8% | 203.7% | ||
| Q4 24 | 35.6% | -628.8% | ||
| Q3 24 | 18.0% | -6.8% | ||
| Q2 24 | -16.4% | -67.1% | ||
| Q1 24 | — | -152.8% |
每股收益（稀释后）PLXRC
| Q4 25 | $-0.06 | $-1.43 | ||
| Q3 25 | $0.03 | $-0.13 | ||
| Q2 25 | $0.00 | $-0.34 | ||
| Q1 25 | $-0.05 | $0.46 | ||
| Q4 24 | $0.10 | $-1.89 | ||
| Q3 24 | $0.03 | $-0.07 | ||
| Q2 24 | $-0.03 | $-0.23 | ||
| Q1 24 | — | $-0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.7M | $207.8M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $48.2M | $1.5B |
| 总资产 | $82.3M | $7.8B |
| 负债/权益比越低杠杆越低 | — | 0.89× |
8季度趋势，按日历期对齐
现金及短期投资PLXRC
| Q4 25 | $14.7M | $207.8M | ||
| Q3 25 | $13.6M | $147.5M | ||
| Q2 25 | $17.9M | $162.9M | ||
| Q1 25 | $19.5M | $205.9M | ||
| Q4 24 | $19.8M | $143.8M | ||
| Q3 24 | $27.4M | $181.3M | ||
| Q2 24 | $23.4M | $226.3M | ||
| Q1 24 | — | $166.0M |
总债务PLXRC
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.1B |
股东权益PLXRC
| Q4 25 | $48.2M | $1.5B | ||
| Q3 25 | $52.9M | $1.8B | ||
| Q2 25 | $49.9M | $1.8B | ||
| Q1 25 | $45.2M | $1.9B | ||
| Q4 24 | $43.2M | $1.8B | ||
| Q3 24 | $32.4M | $2.2B | ||
| Q2 24 | $28.6M | $2.3B | ||
| Q1 24 | — | $2.4B |
总资产PLXRC
| Q4 25 | $82.3M | $7.8B | ||
| Q3 25 | $82.3M | $8.3B | ||
| Q2 25 | $78.5M | $9.3B | ||
| Q1 25 | $73.9M | $10.0B | ||
| Q4 24 | $73.4M | $10.1B | ||
| Q3 24 | $61.6M | $11.3B | ||
| Q2 24 | $91.5M | $11.8B | ||
| Q1 24 | — | $12.0B |
负债/权益比PLXRC
| Q4 25 | — | 0.89× | ||
| Q3 25 | — | 0.78× | ||
| Q2 25 | — | 0.76× | ||
| Q1 25 | — | 0.77× | ||
| Q4 24 | — | 0.73× | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | 0.52× | ||
| Q1 24 | — | 0.46× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.0M | $432.1M |
| 自由现金流经营现金流 - 资本支出 | $1.6M | — |
| 自由现金流率自由现金流/营收 | 17.8% | — |
| 资本支出强度资本支出/营收 | 4.4% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-13.6M | — |
8季度趋势，按日历期对齐
经营现金流PLXRC
| Q4 25 | $2.0M | $432.1M | ||
| Q3 25 | $-3.7M | $434.7M | ||
| Q2 25 | $-5.2M | $-100.3M | ||
| Q1 25 | $-5.1M | $108.5M | ||
| Q4 24 | $4.0M | $274.8M | ||
| Q3 24 | $4.1M | $221.1M | ||
| Q2 24 | $-3.6M | $1.1M | ||
| Q1 24 | — | $23.4M |
自由现金流PLXRC
| Q4 25 | $1.6M | — | ||
| Q3 25 | $-4.2M | — | ||
| Q2 25 | $-5.7M | — | ||
| Q1 25 | $-5.4M | — | ||
| Q4 24 | $3.6M | — | ||
| Q3 24 | $4.0M | — | ||
| Q2 24 | $-3.8M | — | ||
| Q1 24 | — | — |
自由现金流率PLXRC
| Q4 25 | 17.8% | — | ||
| Q3 25 | -23.7% | — | ||
| Q2 25 | -36.2% | — | ||
| Q1 25 | -53.0% | — | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 22.4% | — | ||
| Q2 24 | -28.1% | — | ||
| Q1 24 | — | — |
资本支出强度PLXRC
| Q4 25 | 4.4% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 2.8% | — | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | — | — |
现金转化率PLXRC
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | -31.91× | — | ||
| Q1 25 | — | 1.32× | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
RC
暂无分部数据
